Table 1 Clinical characteristics of all GTN Patients with Brain Metastasis
Characteristic | Patient(n = 109) |
|---|---|
Age (years), median (range) | 28(20–56) |
Gravidity, median (range) | 2(1–8) |
Parity, median (range) | 1(0–4) |
Interval time(mos.) from antecedent pregnancy median (range) | 20(1–288) |
Antecedent pregnancy | |
Abortion | 24(23.8%) |
Mole | 41(40.6%) |
Term | 36(35.6%) |
No. of metastases | |
1 ~ 4 | 86(78.9%) |
5 ~ 8 | 17(15.6%) |
>8 | 6(5.5%) |
Site of metastasisa | |
Brain metastasis | 75(68.8%) |
Brain + liver metastasis | 12(11.0%) |
Brain + kidney metastasis | 10(9.2%) |
Brain + liver + kidney metastasis | 4(3.7%) |
Other sitesb | 8(7.3%) |
Multidrug chemotherapy history | 47(43.9%) |
FIGO, median (range) | 13(5 ~ 23%) |
Pretreatment serum β-hCG level (mIU/mL), median (range) | 19224(62–3049000) |
FAEV regimens | |
Primary treatment | 62(56.1%) |
Salvage treatment | 47(43.9%) |